Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Classes of recommendations


Levels of evidence


Investigational algorithm for patients with coronary artery disease and diabetes

mellitus


Definition, classification, and screening of diabetes

and pre-diabetic glucose abnormalities


Criteria used for glucometabolic classification according

to the WHO (1999) and ADA (1997 and 2003) (values are expressed as venous plasma glucose)


Aetiological classification of glycaemia disordersaa


Conversion factors between plasma and other vehicles for glucose values


Fasting and post-load glucose levels identify

different individuals with asymptomatic diabetes


FINnish Diabetes Risk SCore (FINDRISC) to assess the 10 year risk of type 2 diabetes in adults

Task

Forc

e o

n D

iabete

s and C

VD

(ESC

and E

ASD

) Euro

pean H

eart

Journ

al

20

07

;28

:88

-13

6

Epidemiology of diabetes, IGH, and cardiovascular risk


Age- and gender-specific prevalence of diabetes in 13 European population-based cohorts included in

the DECODE study


Identification of subjects at high risk for CVD or diabetes


Summary of the findings of four lifestyle intervention studies

that aimed at preventing type 2 diabetes in subjects with IGT


Treatment to reduce cardiovascular riskLifestyle and comprehensive management


Mean efficacy of pharmacological treatment options in patients with type 2 diabetes


Percentage of patients achieving pre-defined

intensive treatment targets in the Steno 2 study


Glycaemic targets for the care of patients with

diabetes as recommended by various organizations


Potential downsides of pharmacological treatment modalities in patients with type 2

diabetes


Suggested policy for the selection of glucose-lowering therapy according to the

glucometabolic situation


Treatment to reduce cardiovascular risk - Dyslipidaemia


Subgroups of patients with DM in the major secondary prevention trials with statins and the proportionate risk reduction in patients

with and without diabetes


Treatment to reduce cardiovascular risk - Blood pressure


Treatment effects of antihypertensive drugs in

comparison with placebo or less intensive treatment as reported in randomized

clinical trials


Treatment effects expressed in hazard ratios (95% CI) in randomized clinical trials comparing different

antihypertensive treatments in hypertensive patients with type 2 diabetes


Management of CVD - Coronary artery disease


Treatment options based on accumulated evidence


Recommended treatment targets for patients with diabetes and CAD


Diabetes and coronary revascularization


Trials addressing diabetes and revascularization

for multivessel disease


Revascularization in diabetes patients with multivessel disease in the stent-era


Heart failure and diabetes


Arrhythmias: atrial fibrillation and sudden cardiac death


Peripheral vascular disease


Investigations of the peripheral circulation in diabetic patients


Stroke


Intensive care


Published trials on intensive insulin therapy in critical illness


Health economics and diabetes


Direct medical costs for patients with type 2 diabetes

in eight European countries and percentage of healthcare expenditure in the respective

countries (1998)


Documents

Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136